- Home
- VTMX vs BEAM Comparison
VTMX vs BEAM Comparison
Compare VTMX & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTMX
- BEAM
- Stock Information
- Founded
- VTMX 1998
- BEAM 2017
- Country
- VTMX Mexico
- BEAM United States
- Employees
- VTMX N/A
- BEAM N/A
- Industry
- VTMX
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VTMX
- BEAM Health Care
- Exchange
- VTMX Nasdaq
- BEAM Nasdaq
- Market Cap
- VTMX 2.2B
- BEAM 1.9B
- IPO Year
- VTMX 2023
- BEAM 2020
- Fundamental
- Price
- VTMX $26.15
- BEAM $28.81
- Analyst Decision
- VTMX Buy
- BEAM Buy
- Analyst Count
- VTMX 2
- BEAM 10
- Target Price
- VTMX $33.50
- BEAM $47.67
- AVG Volume (30 Days)
- VTMX 167.0K
- BEAM 1.1M
- Earning Date
- VTMX 02-12-2025
- BEAM 11-05-2024
- Dividend Yield
- VTMX 2.81%
- BEAM N/A
- EPS Growth
- VTMX 2.33
- BEAM N/A
- EPS
- VTMX 0.39
- BEAM N/A
- Revenue
- VTMX $243,239,612.00
- BEAM $349,643,000.00
- Revenue This Year
- VTMX N/A
- BEAM N/A
- Revenue Next Year
- VTMX $21.87
- BEAM $10.82
- P/E Ratio
- VTMX $6.36
- BEAM N/A
- Revenue Growth
- VTMX 18.11
- BEAM 328.73
- 52 Week Low
- VTMX $23.32
- BEAM $20.84
- 52 Week High
- VTMX $41.44
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- VTMX 58.60
- BEAM 56.10
- Support Level
- VTMX $25.13
- BEAM $24.96
- Resistance Level
- VTMX $26.23
- BEAM $29.52
- Average True Range (ATR)
- VTMX 0.74
- BEAM 1.97
- MACD
- VTMX 0.16
- BEAM 0.01
- Stochastic Oscillator
- VTMX 95.40
- BEAM 63.74
About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)
Corporacion Inmobiliaria Vesta SAB de CV is a real estate company dedicated to the development and leasing of industrial buildings and distribution centers in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenues is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.